A study published October 14, 2026, in Nature Aging reports that increased expression of SRSF1, a protein involved in RNA processing and splicing, shifted some age-associated molecular and functional characteristics toward younger states. In treated older mice, the researchers reported slower frailty progression and a 14% increase in median lifespan relative to controls. This is a preclinical lead for geroscience, not proof that human aging can be reversed.
What did the researchers actually do?
Alexandru M. Plesa, Sascha Jung, George M. Church and colleagues developed a machine-learning-based predictor of cellular aging using patterns of gene expression in human fibroblasts, the connective-tissue cells often studied in laboratory aging models. They screened selected genes for their ability to shift gene-expression signatures in older cells toward those of younger cells.
The strongest candidate was SRSF1 (serine/arginine-rich splicing factor 1). SRSF1 helps process precursor messenger RNA into mature RNA messages. Changing its activity can influence which protein variants cells manufacture and how broader gene-expression networks behave. It is not itself a newly invented gene or a ready-to-use longevity drug.
What changed in the cells?
When researchers increased SRSF1 expression in aging fibroblast models, they observed changes consistent with more youthful gene-expression patterns, alongside reduced markers of cellular senescence, protein-maintenance stress and inflammatory signaling. The researchers also reported changes in DNA-repair-associated programs and other aging-related readouts. Such laboratory indicators can reveal mechanisms worth investigating, but do not establish clinical rejuvenation.
A key finding was that the cells continued to behave like fibroblasts rather than activating the pluripotency programs associated with full cellular reprogramming. This matters because researchers seek ways to recover aspects of youthful function without erasing a cell's identity. It does not, by itself, establish that SRSF1 delivery is safe.
What happened in mice?
The team used a gene-delivery approach involving an adeno-associated viral vector with strong liver targeting in older mice. They reported systemic benefits, including 44% slower frailty progression and a 14% increase in median lifespan compared with control mice. The Nature Aging abstract lists 9–10 mice per group for the lifespan analysis. The relatively small groups mean the size and reproducibility of the effect need careful follow-up.
Why does this matter for longevity science?
Much rejuvenation research has investigated partial cellular reprogramming using factors associated with Shinya Yamanaka's discoveries. This study explores a different lever: altering RNA processing and gene-expression networks with one splicing factor. If validated, it may help researchers identify tissue-specific ways to influence multiple aging pathways while attempting to preserve specialized cell function.
The scientific interest is broader than a single gene therapy: the gene-expression-age screening approach may offer a way to identify and compare future candidates. But changes in a transcriptomic or epigenetic clock remain surrogate measures; the clinically important questions concern disease, disability, function, safety and survival.
What is still unknown?
- Replication: Will independent teams reproduce the mouse survival and frailty findings, including in larger groups and different backgrounds?
- Mechanism: Which of SRSF1's RNA-splicing changes actually cause benefits, and which might create harmful side effects?
- Delivery and control: Can expression be targeted and dosed safely in different tissues for sustained periods?
- Long-term safety: Could manipulating a widely used RNA-processing regulator contribute to abnormal growth, altered splicing or other unforeseen effects?
- Human relevance: Do useful outcomes translate beyond cultured cells and animal experiments into rigorous human trials?
MKP assessment
Research significance: high enough to follow closely. Evidence for human anti-aging benefit: not established. The study is a notable example of combining machine learning, aging biology and gene delivery to test a specific mechanism. Its small animal sample and preclinical scope call for disciplined interpretation rather than miracle-cure headlines.
The work should be understood alongside broader geroscience, including senescence research, epigenetic clocks, rapamycin, regenerative medicine and partial reprogramming—not as a replacement for proven preventive care or prescribed treatment.
Discussion questions
How can researchers show that a change in a molecular aging clock reflects meaningful tissue repair? Would a liver-directed approach yield similar benefits in other organs? What scale of independent animal testing should precede human experimentation?
Primary sources and further reading
- Plesa, A. M., Jung, S., Wang, H. H., et al. (2026). Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging. Nature Aging, 6, 2057–2073. DOI: 10.1038/s43587-026-01234-8.
- Wyss Institute at Harvard University (October 14, 2026). Reversing age by reprogramming gene expression networks — institutional explanation of the study.
Editorial note: Published as an educational MKP research review on October 15, 2026. Quantitative results refer to the original preclinical study. This is not medical advice and does not suggest that SRSF1 manipulation or any unapproved gene treatment should be attempted in humans.